Hepatitis delta-associated mortality in HIV/HBV-coinfected patients

Béguelin, Charles; Moradpour, Darius; Sahli, Roland; Suter‐Riniker, Franziska; Lüthi, Alexander U.; Cavassini, Matthias; Günthard, Huldrych F.; Battegay, Manuel; Bernasconi, Enos; Schmid, Patrick; Calmy, Alexandra; Braun, Dominique L; Furrer, Hansjakob; Rauch, Andri; Wandeler, Gilles

doi:10.1016/j.jhep.2016.10.007

Cited by 105 publications

(139 citation statements)

References 29 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…Our study results are consistent with those obtained in other cohorts, where subjects with detectable HDV‐RNA showed worse prognosis in terms of developing liver decompensation, requiring liver transplantation and/or experiencing liver‐related death compared with those having undetectable HDV‐RNA. In our cohort, the rate of patients developing hepatocellular carcinoma was lower than in previous studies.…”

Section: Discussionsupporting

confidence: 91%

“…In addition, 86 (73%) out of 118 of our patients showed detectable HDV‐RNA, a percentage that is in line with that observed in other European cohorts . Patients with detectable HDV‐RNA had liver cirrhosis more often than those in whom it was undetectable, confirming the severity of chronic hepatitis delta infection.…”

Section: Discussionsupporting

confidence: 90%

“…This high variability may be due to the different clinical characteristics of the patients included. Unlike our cohort, these studies included patients with other comorbidities (HIV and/or HCV coinfected subjects) or decompensated liver disease, both factors associated with higher mortality rates …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Long‐term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia

Palom

Rodríguez‐Tajes

Navascués

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Chronic hepatitis delta is a severe liver disease with rapid progression to cirrhosis. The impact of hepatitis delta virus (HDV)‐RNA on disease progression and interferon treatment in a real‐world cohort has been barely explored. Aim To assess the development of clinical events in a cohort of chronic hepatitis delta patients according to the presence or absence of HDV‐RNA Methods Multicentre study at four academic hospitals in Spain included anti‐HDV‐positive patients with compensated liver disease with a follow‐up ≥12 months. Results Among 2888 HBsAg‐positive subjects, 151 (5.2%) tested positive for anti‐HDV, and 118 were included (58% men; median age, 49 years; 73% detectable HDV‐RNA and 30% cirrhosis, most often in subjects with HDV‐RNA). After a median follow‐up of 8 years, subjects with initially detectable HDV‐RNA were more prone to developing cirrhosis (31% vs 0%, P = .002) and/or liver decompensation (28% vs 3%, P = .019). Mortality rate was 0.44 per 1000 person‐months. The probability of a clinical event was 6%, 25%, and 80% according to initial baseline‐event‐anticipation score. HDV‐RNA became undetectable in 21 (24%) subjects either due to interferon or spontaneously (48% vs 52%, P = .29). Liver decompensation was reduced in interferon‐treated patients (13% vs 38%, P = .026). Conclusions Subjects with persistently positive HDV‐RNA had a worse prognosis in terms of clinical events. Baseline‐event‐anticipation score is useful in predicting the risk of developing liver decompensation and hepatocellular carcinoma. Interferon was beneficial in reducing liver decompensation, even in the absence of virological response.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Long‐term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia

Palom

Rodríguez‐Tajes

Navascués

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…20 HDV genotypes 5–7 have only been reported from Africa. However, in the last 5 years, genotypes 5 and 6 have also been found in the UK,21 genotypes 6 and 7 in France22 and genotype 5 in Switzerland 23…”

Section: Resultsmentioning

confidence: 99%

Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis

Chen

Shen

et al. 2018

Gut

278

321

View full text Add to dashboard Cite

show abstract

“…In sub‐Saharan Africa, the estimated prevalence of anti‐HDV has exceeded the global prevalence and around 7 million people are infected by HDV . HBsAg‐positive patients with HDV co‐infection showed higher risk to progress to liver fibrosis or HCC compared to asymptomatic controls . Thus, for better management or prevention of HDV infection, diagnosis and screening for high‐risk populations are recommended .…”

Section: Discussionmentioning

confidence: 99%

Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus

Miao

Zhang

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Summary Hepatitis delta virus (HDV), as a defective sub‐virus that co‐infects with hepatitis B virus, imposes an emerging global health burden. However, genetic characteristics and molecular classification of HDV remain under investigated. In this study, we have systematically retrieved and analysed a large set of HDV full‐length genome sequences and identified novel recombinants. Based on phylogenetic and genetic analyses, we have established an updated classification system for HDV when recombinants were excluded. Furthermore, we have mapped the global distribution of different genotypes and subtypes. Finally, we have compiled a complete set of reference genomes for each subtype and proposed criteria for future identification of novel genotypes and subtypes. Of note, the global distribution map indicates that currently available HDV genetic data remain limited, and thus our proposed classification will likely evolve as future epidemiological data will accumulate. These results will facilitate the future research on the diagnosis, screening, epidemiology, evolution, prevention and clinical management of HDV infection.

show abstract

Hepatitis delta-associated mortality in HIV/HBV-coinfected patients

Cited by 105 publications

References 29 publications

Long‐term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia

Long‐term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia

Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis

Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus

Contact Info

Product

Resources

About